Glaxosmithkline (GSK) Stock
Global healthcare company focused on pharmaceuticals and vaccines. Here's the price, business snapshot, and what's worth knowing about Glaxosmithkline in September 2026.
GlaxoSmithKline PLC (GSK), listed as a sponsored ADR in the US under ticker GSK, is a large, diversified global healthcare company with a market capitalisation of roughly $89 billion. The business focuses on pharmaceuticals and vaccines after spinning off much of its consumer healthcare arm (Haleon) in recent years. Key investor considerations include R&D pipeline progress—particularly in respiratory, HIV and immunology areas—vaccine performance, regulatory approvals and patent expiries. GSK has a history of paying dividends, which may appeal to income-oriented investors, but dividend levels and the share price can fluctuate. Corporate strategy, partnerships and potential M&A are common catalysts. Risks include clinical trial setbacks, pricing and competition, currency and geopolitical exposure, and regulatory scrutiny. This summary is general educational information and not personal financial advice; investing involves risk, values can rise or fall, and past performance is not a reliable indicator. Consult a financial adviser for suitability.
Why It’s Moving
GSK gets fresh pipeline momentum, but analysts still see room for the stock to slip
- GSK advanced its mRNA seasonal flu vaccine into a late-stage trial after mid-stage data showed stronger immune responses than current standard and high-dose shots, reinforcing the company’s vaccine pipeline story.
- Hutchmed’s licensing deal with GSK for an experimental cancer therapy added a fresh pipeline catalyst, pointing to continued deal-making around oncology assets.
- Broader healthcare sentiment has been mixed, and traders are weighing whether recent pipeline wins can offset analyst caution about valuation and execution risk, which helps explain the stock’s downside warning.
GSK gets fresh pipeline momentum, but analysts still see room for the stock to slip
- GSK advanced its mRNA seasonal flu vaccine into a late-stage trial after mid-stage data showed stronger immune responses than current standard and high-dose shots, reinforcing the company’s vaccine pipeline story.
- Hutchmed’s licensing deal with GSK for an experimental cancer therapy added a fresh pipeline catalyst, pointing to continued deal-making around oncology assets.
- Broader healthcare sentiment has been mixed, and traders are weighing whether recent pipeline wins can offset analyst caution about valuation and execution risk, which helps explain the stock’s downside warning.
Sixth Month Growth Performance
When is the next earnings date for GlaxoSmithKline (GSK)?
The next earnings date for GSK is October 28, 2026. It is expected to cover third-quarter 2026 results. That timing fits GSK’s usual quarterly reporting pattern and is the company’s currently announced schedule.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GlaxoSmithKline's stock with a target price of $48.28, indicating potential growth.
Financial Health
GlaxoSmithKline is performing well with strong profits, cash flow, and revenue generation.
Dividend
GlaxoSmithKline's average dividend yield of 4.06% is decent for investors seeking dividend income. If you invested $1000 you would be paid $40.60 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Late-stage trials and approvals can change growth prospects, though clinical setbacks are possible and can affect share value.
Vaccines & R&D
A strong vaccines franchise supports revenue potential, but R&D outcomes are uncertain and require close monitoring.
Global Reach & Risks
Exposure to international markets diversifies sales but brings currency, regulatory and geopolitical risks that can impact performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
